Use of humanized severe combined immunodeficient mice for human vaccine development

Expert Review of Vaccines

Volumn 8, Issue 1, 2009, Pages 113-120

  Koo, Gloria C ^a,b   Hasan, Aisha ^b   O'Reilly, Richard J ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Preclinical model; Severe combined immunodeficient mice; Vaccine development

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; TUMOR CELL VACCINE; VACCINE;

BLOOD CELL; HUMAN; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SCID MOUSE; SENSITIZATION; VACCINATION; VACCINE PRODUCTION; XENOGRAFT;

ANIMALS; HUMANS; MICE; MICE, SCID; MODELS, ANIMAL; RESEARCH; VACCINES;

EID: 58149400832     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.1.113     Document Type: Review

References (50)

1. Bosma GC, Custer CR, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 301, 527-530 (1983).
2. Miller RD, Hogg J, Ozaki JH, Gell D, Jackson SP, Riblet R. Gene for the catalytic subunit of mouse DNA-dependent protein kinase maps to the SCID locus. Proc. Natl Acad. Sci. USA 92, 10792-10795 (1995).
3. Araki R, Fujimori A, Hamatani K et al. Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc. Natl Acad. Sci. USA 94, 2438-2443 (1997).
4. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335(6187), 256-259 (1988).
5. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241, 1632-1639 (1988).
6. Torbett BE, Picchio G, Mosier DE. hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol. Rev. 124, 139-164 (1991).
7. McCune JM. Animal models of HIV-1 disease. Science (NY) 278(5346), 2141-2142 (1997).
8. Shultz LD, Schweitzer PA, Christianson SW et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-SCID mice. J. Immunol. 154(1), 180-191 (1995).
9. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7(2), 118-130 (2007). •• Excellent review on the derivation of the various severe combined immunodeficient (SCID) mice.
10. Nakajima H, Shores E, Noguchi M, Leonard WJ. The common cytokine receptor g-chain plays an essential role in regulating lymphoid homeostasis. J. Exp. Med. 185, 189-195 (1997).
11. Ito M, Hiramatsu H, Kobayashi K et al. NOD/SCID/?(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9), 3175-3182 (2002).
12. + cells in nonobese diabetic/Shi-SCID, IL-2 receptor ? null mice. J. Immunol. 169(1), 204-209 (2002).
13. Traggiai E, Chicha L, Mazzucchelli L et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (NY) 304(5667), 104-107 (2004).
14. Legrand N, Weijer K, Spits H. Experimental models to study development and function of the human immune system in vivo. J. Immunol. 176(4), 2053-2058 (2006).
15. Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and myeloid cell development in NOD/LtSz-SCID IL2R ? null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174(10), 6477-6489 (2005).
16. Ito M, Kobayashi K, Nakahata T. NOD/Shi-SCID IL2R? (null) (NOG) mice more appropriate for humanized mouse models. Curr. Top. Microbiol. Immunol. 324, 53-76 (2008). •• Excellent review on the subject.
17. Manz MG. Human-hemato-lymphoidsystem mice: opportunities and challenges. Immunity 26(5), 537-541 (2007). •• In-depth perspective of where we are in SCID mouse research.
18. Engelhard VH, Lacy E, Ridge JP. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J. Immunol. 146(4), 1226-1232 (1991).
19. Marron MP, Graser RT, Chapman HD, Serreze DV. Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc. Natl Acad. Sci. USA 99(21), 13753-13758 (2002).
20. Camacho RE, Wnek R, Shah K et al. Intra-thymic/splenic engraftment of human T cells in HLA-DR1 transgenic NOD/SCID mice. Cell Immunol. 232(1-2), 86-95 (2004).
21. Habu S, Fukui H, Shimamura K et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127, 34 (1981).
22. King M, Pearson T, Shultz LD et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-SCID mice bearing a targeted mutation in the IL-2 receptor ? chain gene. Clin. Immunol. 126(3), 303-314 (2008).
23. Okada M, Okuno Y, Hashimoto S et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 25, 3038-3040 (2007).
24. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 108(5), 1770-1773 (2006).
25. Papanicolaou GA, Latouche JB, Tan C et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 102(7), 2498-2505 (2003).
26. Rossi MI, Medina K, Garrett K et al. Relatively normal human lymphopoiesis but rapid turnover of newly formed B cells in transplanted nonobese diabetic/SCID mice. J. Immunol. 167, 3033-3042 (2001).
27. Camacho RE, Wnek R, Fischer P et al. Characterization of the NOD/SCID-[Tg] DR1 mouse expressing HLA-DRB1*01 transgene: a model of SCID-hu mouse for vaccine development. Exp. Hematol. 35, 1219-1230 (2007).
28. Barabé F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 316, 600-604 (2007).
29. Koehne G, Doubrovin M, Doubrovina E et al. HSV-TK-transduced antigen-specific lymphocytes: serial in vivo imaging of the targeted migration of human. Nat. Biotechnol. 21, 405-413 (2003).
30. Doubrovin MM, Doubrovina E, Zanzonico P, Sadelain M, Larson SM, O'Reilly RJ. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res. 67, 11959-11969 (2007).
31. Dobrenkov K, Olszewska M, Likar Y et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J. Nucl. Med. 49, 1162-1170 (2008).
32. Yan Y, Salomon O, McGuirk J et al. Growth pattern and clinical correlation of subcutaneously inoculated human primary acute leukemias in severe combined immunodeficiency mice. Blood 88(8), 3137-3146 (1996).
33. + cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22, 1207-1213 (2008).
34. Simpson-Abelson MR, Sonnenberg GF, Takita H et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of nondisrupted pieces of human lung tumor into NOD-SCID IL2Rγ(null) mice. J. Immunol. 180, 7009-7018 (2008).
35. Pober JS, Bothwell AL, Lorber MI et al. Immunopathology of human T cell responses to skin, artery and endothelial cell grafts in the human peripheral blood lymphocyte/severe combined immunodeficient mouse. Springer Semin. Immunopathol. 25, 167-180 (2003). •• Excellent paradigm of studying and testing peripheral blood mononuclear cells and skin tissue together in the SCID mouse.
36. Moffat J, Mo C, Cheng JJ et al. Functions of the C-terminal domain of Varicella zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J. Virol. 78, 12406-12415 (2004).
37. Taylor RA, Cowin P, Cunha GR et al. Formation of human prostate tissue from embryonic stem cells. Nat. Methods 3, 179-181 (2006).
38. -/- mice: functional inactivation of p53 in developing T cells. Blood 104(13), 3886-3893 (2004).
39. Pearson T Greiner D, Shultz LD. Creation of "humanized" mice to study human immunity. Curr. Protoc. Immunol. 15, 21 (2008). • Demonstrates good technical protocols.
40. Pearson T Greiner D, Shultz LD. Humanized SCID mouse models for biomedical research. Curr. Top. Microbiol. Immunol. 324, 25-51 (2008).
41. Melkus MW, Estes J, Padgett-Thomas A et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 11, 1316-1322 (2006).
42. Tonomura N, Habiro K, Shimizu A, Sykes M, Yang YG. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood 111, 4293-4296 (2008).
43. -/- mice. Proc. Natl Acad. Sci. USA 103(43), 15951-15956 (2006).
44. -/- mice in vivo. Blood 112(7), 2858-2868 (2008).
45. Yajima M, Imadome K, Nakagawa A et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 198(5), 673-682 (2008).
46. Mosier DE, Picchio GR, Kirven MB et al. EBV-induced human B cell lymphomas in hu-PBL-SCID mice. AIDS Res. Hum. Retroviruses 8(5), 735-740 (1992).
47. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin. Exp. Immunol. 137(3), 513-520 (2004).
48. + T cell responses in humanized mice vaccinated with influenza virus vaccines. Blood 112(9), 3671-3678 (2008).
49. Hasan A, Kollen WJ, Selvakumar A, Trivedi D, Sadelain M, O'Reilly RJ. A panel of artificial antigen-presenting cells (AAPC) expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both subdominant and dominant viral epitopes for adoptive therapy. Blood 110(11), 2589 (2007).
50. O'Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen WJ, Koehne G. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol. Res. 38(1-3), 237-250 (2007).